About NoNO Inc.
NoNO Inc. is a private, clinical-stage biotherapeutics company dedicated to the research, development and commercialization of pharmaceuticals for the treatment of common health disorders with unmet needs, including stroke, traumatic brain injury, and pain.
NoNO is headquartered in Toronto, Canada.
NoNO’s therapeutic products all stem from fundamental academic research completed by two of its founding scientists, Dr. Michael Tymianski and Dr. Michael Salter, on central nervous system (CNS) biological targets with well-characterized mechanisms. The company has identified three important therapeutic targets and corresponding products: NA-1, a proprietary inhibitor of PSD-95 proteins found in synapses; TRPM7 ion channel antagonists; and inhibitors of Src-ND2 interactions. The company’s lead therapeutic, NA-1, has successfully advanced through Phase 1 and Phase 2 trials in the United States and Canada and is being advanced into multiple clinical indications including Acute Ischemic Stroke, Subarachnoid Hemorrhage and procedurally-induced strokes.